The people
What they build
Open roles via the TechTO Job Board
Working at BioRender
Browse open roles across the community on the TechTO Job Board — Canada’s most connected tech network. BioRender’s roles show up here whenever they post.
Open roles on the TechTO Job Board ↗Or their own careers page: biorender.com/careers ↗Jobs live on jobs.techto.org — the only structured source. We link to it rather than scraping career sites, so the board is always the source of truth.
On the TechTO stage
Life Sciences: An Industry Stuck in the Middle Ages
Watch on YouTube ↗What YC Doesn't Tell Canadian Founders
Watch on YouTube ↗Every talk is searchable — ask the archive about BioRender ↗
About
BioRender started when co-founder Shiz Aoki, a scientific illustrator, and her co-founders realized biology had no standard visual language — researchers were drawing figures by hand in PowerPoint or waiting on the roughly 30 trained science illustrators graduating each year. The company went through Y Combinator in early 2018 (W18), returned to Toronto, and built a drag-and-drop tool and icon library that scientists use to make publication-ready figures. It has been profitable since 2019 and, as co-founder Ryan Marien told the TechTO stage in February 2026, has grown roughly 70-100x since reaching profitability.
Backers
Y Combinator (W18) and a Series A in June 2023. Largely bootstrapped and profitable since 2019; a December 2025 secondary led by Dimension Capital valued the company at $900M.
More from TechTO Ă—6
Quick answers
What does BioRender do?
BioRender is a web tool that lets scientists build publication-ready figures from a library of 50,000+ biology icons and templates, instead of drawing them in PowerPoint or hiring an illustrator.
Who founded BioRender?
Shiz Aoki (CEO), Katya Shteyn (CTO) and Ryan Marien, in 2017 in Toronto. It went through Y Combinator in early 2018 (W18).
Is BioRender profitable?
Yes. Co-founder Ryan Marien has said BioRender has been profitable since 2019 and grew roughly 70-100x since reaching profitability. A December 2025 secondary led by Dimension Capital valued it at $900M.